ROLE OF PHARMACOGENOMICS IN INDIVIDUALIZED PHARMACOTHERAPY

Authors

  • Henry T. Collins Department of Clinical Pharmacology and Precision Medicine, Oxford Centre for Biomedical Research, United Kingdom

Keywords:

pharmacogenomics; pharmacogenetics; precision medicine; individualized pharmacotherapy; drug–gene interaction; clinical decision support; adverse drug reactions.

Abstract

Pharmacogenomics (PGx) aims to use inherited genetic variation to improve the selection and dosing of medicines. Its clinical relevance is strongest when genetic information is combined with conventional determinants of drug response, including age, organ function, interacting medicines, disease severity and treatment goals. This structured review evaluates the role of PGx in individualized pharmacotherapy, emphasizing actionable gene–drug pairs, evidence from implementation studies, guideline-based prescribing, and practical barriers to routine use. International evidence was synthesized from peer-reviewed clinical trials, implementation studies, CPIC guidelines, and major reviews. The findings show that PGx is most mature for drugs affected by polymorphic drug-metabolizing enzymes, transporters, immune-risk alleles, and selected pharmacodynamic pathways. Examples include CYP2C19-guided antiplatelet therapy, CYP2D6/CYP2C19-guided antidepressant prescribing, TPMT/NUDT15-guided thiopurine dosing, SLCO1B1/ABCG2/CYP2C9-guided statin therapy, and multigene approaches for preventing adverse drug reactions. The PREPARE implementation study demonstrated that a 12-gene panel can reduce clinically relevant adverse drug reactions when prescribing is adjusted according to established recommendations. Nevertheless, clinical utility depends on test quality, population representation, guideline concordance, electronic decision support, reimbursement, and clinician education. PGx should therefore be viewed as a component of precision pharmacotherapy rather than an isolated genetic test. Future progress will depend on pre-emptive panel testing, interoperable electronic health records, better evidence in diverse populations, and integration of genomic data with therapeutic drug monitoring and other clinical biomarkers.

References

1.Caudle, K. E., et al. (2025). Advancing clinical pharmacogenomics worldwide through the Clinical Pharmacogenetics Implementation Consortium (CPIC). Clinical Pharmacology & Therapeutics, 118(6), 1512–1522. https://doi.org/10.1002/cpt.70005

2.Swen, J. J., van der Wouden, C. H., Manson, L. E. N., et al. (2023). A 12-gene pharmacogenetic panel to prevent adverse drug reactions: An open-label, multicentre, controlled, cluster-randomised crossover implementation study. The Lancet, 401(10374), 347–356. https://doi.org/10.1016/S0140-6736(22)01841-4

3.Lee, C. R., Luzum, J. A., Sangkuhl, K., et al. (2022). Clinical Pharmacogenetics Implementation Consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clinical Pharmacology & Therapeutics, 112(5), 959–967. https://doi.org/10.1002/cpt.2526

4.Bousman, C. A., Stevenson, J. M., Ramsey, L. B., et al. (2023). Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. Clinical Pharmacology & Therapeutics, 114(1), 51–68. https://doi.org/10.1002/cpt.2903

5.Cooper-DeHoff, R. M., Niemi, M., Ramsey, L. B., et al. (2022). The Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms. Clinical Pharmacology & Therapeutics, 111(5), 1007–1021. https://doi.org/10.1002/cpt.2557

6.Maillard, M., Schwab, M., Whirl-Carrillo, M., et al. (2026). Clinical Pharmacogenetics Implementation Consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2025 update. Clinical Pharmacology & Therapeutics, 119(4), 916–927. https://doi.org/10.1002/cpt.70209

7.Johnson, J. A., Caudle, K. E., Gong, L., et al. (2017). Clinical Pharmacogenetics Implementation Consortium guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clinical Pharmacology & Therapeutics, 102(3), 397–404. https://doi.org/10.1002/cpt.668

8.Abdullah-Koolmees, H., van Keulen, A. M., Nijenhuis, M., & Deneer, V. H. M. (2020). Pharmacogenetics guidelines: Overview and comparison of the DPWG, CPIC, CPNDS, and RNPGx guidelines. Frontiers in Pharmacology, 11, 595219. https://doi.org/10.3389/fphar.2020.595219

9.Kabbani, D., Akika, R., Wahid, A., Daly, A. K., Cascorbi, I., & Zgheib, N. K. (2023). Pharmacogenomics in practice: A review and implementation guide. Frontiers in Pharmacology, 14, 1189976. https://doi.org/10.3389/fphar.2023.1189976

10.Smith, D. M., Douglas, M. P., Aquilante, C. L., et al. (2025). Progress in pharmacogenomics implementation in the United States: Barrier erosion and remaining challenges. Clinical Pharmacology & Therapeutics, 118(4), 778–789. https://doi.org/10.1002/cpt.3736

11.Mai, C.-W., Sridhar, S. B., Karattuthodi, M. S., et al. (2024). Scoping review of enablers and challenges of implementing pharmacogenomics testing in primary care settings. BMJ Open, 14(11), e087064. https://doi.org/10.1136/bmjopen-2024-087064

12.Hall, B. T., Eken, E., et al. (2025). Implementing pharmacogenomics clinical decision support: A comprehensive tutorial on how to integrate the Epic Genomics Module. Clinical Pharmacology & Therapeutics, 117(6), 1670–1681. https://doi.org/10.1002/cpt.3599

13.Gawronski, B. E., Fofanova, I., Miranda, A. M., et al. (2025). Implementation of clinical pharmacogenetic testing in medically underserved patients: A narrative review. Pharmacogenomics, 26(3–4), 107–119. https://doi.org/10.1080/14622416.2025.2490461

14.Kusljic, S., & Luzum, J. A. (2024). It is time for educators to act: Pharmacogenomics education and its implementation into clinical practice. Pharmacogenomics, 25(10–11), 425–427. https://doi.org/10.1080/14622416.2024.2392482

15.Whirl-Carrillo, M., Huddart, R., Gong, L., Sangkuhl, K., Thorn, C. F., Whaley, R., & Klein, T. E. (2021). An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clinical Pharmacology & Therapeutics, 110(3), 563–572.

Published

2026-09-24